The Ali Massumi Cardiac Arrhythmia Symposium 2022

The field of cardiac electrophysiology has evolved from a specialty that primarily managed arrhythmias with drug therapy to one with an expanded role of various nonpharmacologic therapies in detecting and terminating arrhythmias. Representative of this development are the rapidly evolving treatment options for patients with ventricular tachycardia and fibrillation (VT/VF), the most common cause of sudden cardiac death. Pharmacotherapy has not proven to be an adequate treatment option for many of these patients. Although implantable cardioverter defibrillators (ICDs) are effective in terminating VT/VF, but repetitive shocks significantly impair quality of life, and inappropriate ICD shocks in patients with heart failure are associated with increased mortality. Percutaneous catheter ablation has evolved as a promising therapy, particularly in patients with recurrent VT refractory to drugs.

There have also been recent changes to the way we manage patients with atrial fibrillation (AF). Guidelines for the use of anticoagulants have been updated and expanded. There are non-pharmacologic therapies now available to prevent embolic stroke in patients who are at increased risk of bleeding. Catheter ablation for AF has become a mainstream treatment option. New catheters with force sensing technology have improved outcomes and reduced complications.

The Ali Massumi Cardiac Arrhythmia Symposium is designed to provide cardiac electrophysiologists, cardiologists, internists, fellows, cath lab technicians, family and general practitioners and associated professionals with state-of-the-art information on the fundamental mechanisms of cardiac arrhythmias and the best practice approaches to clinical diagnosis, evaluation, and management of abnormal heart rhythms.

Accreditation

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

8:00 a.m.     Welcome

Session I

8:15     Early AF Ablation | Oussama Wazni, MD

8:45     Ablation for Persistent Afib | Abdi Rasekh, MD

9:15     Laser Lead Extraction | John Seger, MD

9:45     Panel Discussion with Q&A

10:00  Break

Session II

10:15     POTS | Mehdi Razavi, MD

10:45     Cardiac Neuro Ablation | Joanna Molina-Razavi, MD

11:15      Left Atrial Appendage Occlusion | Dhanunjaya DJ Lakkireddy, MD

11:45      Panel Discussion with Q&A

Session III

12:00    EP Jeopardy | Wilson Lam, MD

12:15      Lunch

1:15        EP Jeopardy | Wilson Lam, MD

Session IV

1:45       The Innovative Role of Pacemaker in the Treatment of Central Sleep Apnea | Hamid Afshar, MD

2:15       VT | Mohammad Saeed, MD

2:45       Novel Devices for Heart Failure Management | Mihail Chelu, MD

3:15       Panel Discussion and Q&A

3:30      MOC, Evaluation, Closing Remarks and Adjourn

3:45       Adjourn